Log In
Print
BCIQ
Print
Print this Print this
 

Cetuximab-based bispecific zybody

  Manage Alerts
Collapse Summary General Information
Company Zyngenia Inc.
DescriptionZybody targeting EGFR and epidermal growth factor receptor 3 (EGFR3; HER3; ErbB3)
Molecular Target Epidermal growth factor receptor (EGFR) ; Epidermal growth factor receptor 3 (EGFR3) (HER3) (ErbB3)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today